Premium
Cytokinetics Inc (CYTK)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Dr. Edward M. KayeIndependent Director | -2,93k | 223,17k | Vente | 76,09 | 10,28k | -22,19% |
| 2026-06-01 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -15,00k | 762,30k | Derivative Exercise and Sale | 23,26 - 74,08 | 1,59k | - |
| 2026-06-01 | Ms. B. Lynne ParshallIndependent Director | -5,00k | 370,40k | Vente | 74,08 | 15,78k | -24,06% |
| 2026-05-27 | Mr. Robert I. BlumCEO, President & Director | -7,50k | 579,08k | Vente | 77,21 | 239,78k | -3,03% |
| 2026-05-19 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -3,50k | 237,62k | Derivative Exercise and Sale | 7,80 - 75,69 | 98,66k | - |
| 2026-05-14 | Mr. Robert I. BlumCEO, President & Director | -7,50k | 584,40k | Vente | 77,92 | 247,28k | -2,94% |
| 2026-05-05 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -3,50k | 243,50k | Derivative Exercise and Sale | 7,80 - 77,37 | 98,66k | - |
| 2026-05-05 | Dr. Wendell D. WierengaIndependent Director | -4,03k | 252,40k | Derivative Exercise and Sale | 12,40 - 75,00 | 32,64k | - |
| 2026-05-05 | Mr. Sung H. LeeEVP & CFO | -23,91k | 1,84M | Vente | 76,87 | 2,15k | -91,74% |
| 2026-05-05 | Dr. John Tannahill HendersonIndependent Chairman | -20,00k | 1,37M | Derivative Exercise and Sale | 7,61 - 75,97 | 67,99k | - |
| 2026-05-05 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -11,33k | 432,01k | Derivative Exercise and Sale | 39,13 - 77,25 | 1,59k | - |
| 2026-05-01 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -15,86k | 434,01k | Derivative Exercise and Sale | 37,63 - 65,00 | 1,59k | - |
| 2026-04-30 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -15,00k | 600,00k | Derivative Exercise and Sale | 23,26 - 63,26 | 1,59k | - |
| 2026-04-29 | Mr. Robert I. BlumCEO, President & Director | -7,50k | 447,15k | Vente | 59,62 | 254,78k | -2,86% |
| 2026-04-21 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -3,50k | 202,62k | Derivative Exercise and Sale | 7,80 - 65,69 | 98,66k | - |
| 2026-04-15 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -7,45k | 491,78k | Vente | 66,02 | 1,59k | -82,42% |
| 2026-04-15 | Mr. Robert I. BlumCEO, President & Director | -7,50k | 490,35k | Vente | 65,38 | 262,28k | -2,78% |
| 2026-04-07 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -4,50k | 255,09k | Derivative Exercise and Sale | 7,80 - 65,21 | 98,66k | - |
| 2026-04-01 | Mr. Robert I. BlumCEO, President & Director | -7,50k | 499,73k | Vente | 66,63 | 269,78k | -2,70% |
| 2026-03-31 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -3,64k | 236,54k | Vente | 65,00 | 9,04k | -28,71% |
| 2026-03-17 | Mr. Sung H. LeeEVP & CFO | -4,94k | 306,71k | Vente | 62,15 | 87,13k | -5,36% |
| 2026-03-17 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -10,47k | 650,68k | Vente | 62,07 - 62,15 | 14,61k | -41,76% |
| 2026-03-17 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -12,03k | 747,85k | Vente | 62,15 | 98,66k | -10,87% |
| 2026-03-17 | Mr. Robert I. BlumCEO, President & Director | -36,60k | 2,27M | Vente | 62,15 | 277,28k | -11,66% |
| 2026-03-16 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -1,71k | 104,30k | Vente | 61,03 | 23,15k | -6,88% |
| 2026-03-09 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -2,58k | 156,78k | Vente | 60,72 | 5,01k | -34,03% |
| 2026-03-09 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,91k | 176,51k | Vente | 60,72 | 86,38k | -3,26% |
| 2026-03-09 | Mr. Robert I. BlumCEO, President & Director | -7,93k | 481,57k | Vente | 60,72 | 242,85k | -3,16% |
| 2026-03-02 | Ms. B. Lynne ParshallIndependent Director | -5,00k | 306,05k | Vente | 61,21 | 10,60k | -32,05% |
| 2026-03-02 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -886,00 | 21,26k | Derivative Exercise and Sale | 37,63 - 61,62 | 1,59k | - |
| 2026-02-05 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -15,00k | 580,05k | Derivative Exercise and Sale | 23,26 - 61,93 | 1,59k | - |
| 2026-02-02 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -886,00 | 21,68k | Derivative Exercise and Sale | 37,63 - 62,10 | 1,59k | - |
| 2026-01-05 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -15,00k | 555,30k | Derivative Exercise and Sale | 23,26 - 60,28 | 1,59k | - |
| 2026-01-02 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -913,00 | 56,69k | Vente | 62,09 | 1,59k | -36,51% |
| 2026-01-02 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -885,00 | 22,59k | Derivative Exercise and Sale | 37,63 - 63,16 | 1,59k | - |
| 2025-12-29 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -1,81k | 112,95k | Vente | 62,44 | 2,50k | -41,97% |
| 2025-12-22 | Mr. Robert I. BlumCEO, President & Director | -2,94k | 184,08k | Sale to Issuer | 62,72 | 234,28k | -1,24% |
| 2025-12-22 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -1,02k | 63,72k | Sale to Issuer | 62,72 | 81,29k | -1,23% |
| 2025-12-22 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -675,00 | 42,34k | Sale to Issuer | 62,72 | 4,31k | -13,54% |
| 2025-12-22 | Mr. Sung H. LeeEVP & CFO | -805,00 | 50,49k | Sale to Issuer | 62,72 | 17,92k | -4,30% |
| 2025-12-22 | Mr. Robert I. BlumCEO, President & Director | 40,81k | 272,18k | Derivative Exercise and Retained Stock | 6,67 | 225,69k | 22,07% |
| 2025-12-22 | Mr. Robert I. BlumCEO, President & Director | -30,43k | 1,87M | Derivative Exercise and Sale | 6,67 - 68,18 | 225,69k | - |
| 2025-12-22 | Dr. Wendell D. WierengaIndependent Director | -20,00k | 1,17M | Derivative Exercise and Sale | 7,61 - 66,14 | 32,44k | - |
| 2025-12-16 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,20k | 111,41k | Derivative Exercise and Sale | 10,60 - 61,24 | 78,30k | - |
| 2025-12-08 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -1,04k | 27,96k | Derivative Exercise and Sale | 39,13 - 65,96 | 1,81k | - |
| 2025-12-05 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -52,49k | 1,69M | Derivative Exercise and Sale | 23,26 - 65,95 | 1,81k | - |
| 2025-12-03 | Mr. Sung H. LeeEVP & CFO | -1,56k | 101,43k | Sale to Issuer | 65,02 | 14,42k | -9,76% |
| 2025-12-03 | Mr. Andrew M. CallosExec. VP & Chief Commercial Officer | -1,37k | 88,95k | Sale to Issuer | 65,02 | 1,81k | -43,07% |
| 2025-12-03 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,06k | 133,81k | Sale to Issuer | 65,02 | 78,30k | -2,56% |
| 2025-12-03 | Mr. Robert I. BlumCEO, President & Director | -5,93k | 385,57k | Sale to Issuer | 65,02 | 184,88k | -3,11% |
| 2025-12-02 | Dr. John Tannahill HendersonIndependent Chairman | -8,75k | 471,63k | Derivative Exercise and Sale | 10,00 - 63,90 | 67,33k | - |
| 2025-12-02 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,20k | 117,24k | Derivative Exercise and Sale | 10,60 - 63,89 | 76,36k | - |
| 2025-12-01 | Dr. Edward M. KayeIndependent Director | -28,06k | 1,49M | Derivative Exercise and Sale | 12,40 - 66,72 | 2,64k | - |
| 2025-12-01 | Dr. Robert A. HarringtonIndependent Director | -2,15k | 143,62k | Vente | 66,80 | 11,21k | -16,09% |
| 2025-11-19 | Ms. B. Lynne ParshallIndependent Director | -5,00k | 323,65k | Vente | 64,73 | 15,60k | -24,27% |
| 2025-11-18 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,20k | 122,87k | Derivative Exercise and Sale | 10,60 - 66,45 | 76,36k | - |
| 2025-11-11 | Dr. Edward M. KayeIndependent Director | -5,18k | 286,80k | Derivative Exercise and Sale | 9,66 - 65,08 | 2,64k | - |
| 2025-11-05 | Mr. Robert I. BlumCEO, President & Director | -2,00k | 0,00 | Other Disposition | - | 179,25k | -1,10% |
| 2025-11-04 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,30k | 112,34k | Derivative Exercise and Sale | 10,60 - 59,55 | 76,36k | - |
| 2025-10-30 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 314,30k | Vente | 62,86 | 181,25k | -2,68% |
| 2025-10-27 | Dr. Wendell D. WierengaIndependent Director | -4,38k | 212,98k | Derivative Exercise and Sale | 10,00 - 58,68 | 32,44k | - |
| 2025-10-21 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,11k | 100,24k | Derivative Exercise and Sale | 10,60 - 58,22 | 76,36k | - |
| 2025-10-07 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 99,92k | Derivative Exercise and Sale | 10,60 - 60,56 | 76,36k | - |
| 2025-10-06 | Dr. Edward M. KayeIndependent Director | -6,76k | 405,42k | Vente | 60,00 | 2,45k | -73,43% |
| 2025-10-01 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 275,25k | Vente | 55,05 | 191,25k | -2,55% |
| 2025-09-30 | Dr. Edward M. KayeIndependent Director | -6,70k | 368,76k | Vente | 55,08 | 9,20k | -42,11% |
| 2025-09-23 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 77,36k | Derivative Exercise and Sale | 10,60 - 49,28 | 76,36k | - |
| 2025-09-15 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 248,85k | Vente | 49,77 | 196,25k | -2,48% |
| 2025-09-09 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 81,38k | Derivative Exercise and Sale | 10,60 - 51,29 | 76,36k | - |
| 2025-09-02 | Dr. Edward M. KayeIndependent Director | -6,76k | 337,80k | Vente | 50,00 | 15,90k | -29,82% |
| 2025-09-02 | Dr. Robert A. HarringtonIndependent Director | -2,15k | 104,64k | Vente | 48,67 | 13,16k | -14,04% |
| 2025-09-02 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 243,80k | Vente | 48,76 | 201,25k | -2,42% |
| 2025-08-19 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 55,42k | Derivative Exercise and Sale | 10,60 - 38,31 | 76,36k | - |
| 2025-08-15 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 192,10k | Vente | 38,42 | 206,25k | -2,37% |
| 2025-08-05 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 51,48k | Derivative Exercise and Sale | 10,60 - 36,34 | 76,36k | - |
| 2025-07-29 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 182,25k | Vente | 36,45 | 211,25k | -2,31% |
| 2025-07-22 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 53,74k | Derivative Exercise and Sale | 10,60 - 37,47 | 76,36k | - |
| 2025-07-14 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 190,75k | Vente | 38,15 | 216,25k | -2,26% |
| 2025-07-08 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 46,32k | Derivative Exercise and Sale | 10,60 - 33,76 | 76,36k | - |
| 2025-07-01 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 167,75k | Vente | 33,55 | 221,25k | -2,21% |
| 2025-06-17 | Dr. Fady Ibraham MalikExec. VP of Research & Development | -2,00k | 44,62k | Derivative Exercise and Sale | 10,60 - 32,91 | 76,36k | - |
| 2025-06-16 | Mr. Robert I. BlumCEO, President & Director | -5,00k | 169,00k | Vente | 33,80 | 226,25k | -2,16% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
